EUCTR2006-004513-18-ES进行中（未招募）不适用
Randomized, Double-Blind, Active- and Placebo-Controlled, Parallel Group, Multicenter Study to Evaluate the Efficacy and Safety of Multiple Doses of CG5503 Immediate Release Formulation in the Treatment of Acute Pain From Total Hip Replacement Surgery Followed by a Voluntary Open-Label ExtensionEstudio aleatorizado, en doble ciego, controlado con producto activo y con placebo, de grupos paralelos y multicéntrico, para evaluar la eficacia y la seguridad de distintas dosis de CG5503 en formulación de liberación inmediata en el tratamiento del dolor agudo consecuencia de la cirugía de artroplastia total de cadera, seguido por una extensión abierta de carácter voluntario
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.0 个研究点目标入组 1,100 人开始时间: 2007年7月9日最近更新:
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 入组人数
- 1,100
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Man or woman, between 18 to 80 years of age, inclusive
- •Signed an informed consent document indicating that they understand the purpose of and procedures required for the study and are willing to participate in the study
- •Physical status rated as =3 on the American Society of Anesthesiologist (ASA) rating scale (see Attachment 1)
- •Scheduled to undergo standard primary (non-revision) unilateral total hip replacement surgery due to non-inflammatory degenerative joint disease (NIDJD).
- •Baseline pain intensity =4 on an 11-point (0 to 10) Pain Intensity NRS, rated within 30 minutes before randomization
- •Qualifying baseline pain intensity measurements occur within 6 hours of the termination of PCA (after a minimum of 12 hours of PCA), during the postoperative surgical period.
- •Must be able to complete all study related procedures and requirements throughout the study period
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •History of seizure disorder or epilepsy
- •Evidence of active infections that may spread to other areas of the body (e.g., osteomyelitis, pyogenic infection of the hip, Hepatitis B or C, or other overt infections) or a history human immunodeficiency virus (HIV) 1 or 2.
- •Acute crystal-induced arthropathy within the previous 6 months before the screening period of the study
- •Has laboratory values reflecting severe renal insufficiency indicated by a creatinine clearance =30 mg/min.
- •Has laboratory values consistent with significant hepatic impairment based on alanine aminotransferase (ALT) or aspartate aminotransferase (AST) values greater than 3 times the upper limit of normal (ULN); or evidence of significant anemia indicated by hemoglobin (Hgb) levels =8
- •Uncontrolled or poorly controlled post-traumatic stress disorder generalized anxiety disorder (GAD), depression, psychiatric or other significant medical conditions
- •Treated with anticonvulsants, monoamine oxidase inhibitors, tricyclic antidepressants, neuroleptics, or serotonin norepinephrine reuptake inhibitor (SNRI) within 2 weeks before screening, (selective serotonin reuptake inhibitor [SSRI] treatments are allowed if taken for at least 30 days before the screening period of the study at an unchanged dose)
- •Treated with a daily opioid analgesic or combination opioid analgesic, other than those containing tramadol or codeine, for more than 30 days before screening
- •Contraindications to, history of allergy to, or hypersensitivity to CG5503, Oxycodone, hydromorphone, morphine, or fentanyl, or their excipients.
- •Systemic steroid therapy within 3 months before screening, excluding inhalers or a 1-time intraoperative dose
- •Undergoing concomitant surgical procedures in addition to primary total hip replacement
- •History of malignancy within the past 2 years before the start of the study, with the exception of basal cell carcinoma
- •History of alcohol or drug abuse in the investigator’s judgment based on subject history and physical examination
研究者
相似试验
进行中（未招募）
1 期
Randomized, Double-Blind, Active- and Placebo-Controlled, Parallel Group, Multicenter Study to Evaluate the Efficacy and Safety of Multiple Doses of CG5503 Immediate Release Formulation in the Treatment of Acute Pain From Total Hip Replacement Surgery Followed by a Voluntary Open-Label ExtensiopainMedDRA version: 8.1Level: LLTClassification code 10033371Term: PainEUCTR2006-004513-18-FRJohnson & Johnson Pharmaceutical Research & Development, L.L.C.
进行中（未招募）
不适用
Randomized, Double-Blind, Active- and Placebo-Controlled, Parallel Group, Multicenter Study to Evaluate the Efficacy and Safety of Multiple Doses of CG5503 Immediate Release Formulation in the Treatment of Acute Pain From Total Hip Replacement Surgery Followed by a Voluntary Open-Label ExtensioEUCTR2006-004513-18-FIJohnson & Johnson Pharmaceutical Research & Development, L.L.C.1,100
进行中（未招募）
1 期
Randomized, double-blind, placebo and active controlled study of the activity ofSAR407899A single-dose on the ability to increase duration of penile rigidity,under experimental condition, in patients with mild to moderate erectiledysfunction - RHOKETMild to moderate erectile dysfunctionMedDRA version: 11.1Level: LLTClassification code 10061461Term: <Manually entered code. Term in E.1.1>EUCTR2009-009936-56-FRsanofi-aventis recherche et développement24
进行中（未招募）
不适用
Clinical trial to evaluate the clinical effect and safety of a triple combination of ibuprofen, magnesium and vitamin C in the treatment of acute pain in temporomandibular disorders (TMD).Temporomandibular joint dysfunction syndrome.EUCTR2014-003790-41-ESSpherium Biomed
暂停
不适用
Safety, tolerability, pharmacokinetic (PK) and pharmacodynamic (PD) study with ENX-201Multiple Sclerosis (relapses)NL-OMON23997EnhanX Biopharm Inc.12